Belzona slows down mold and mildew issue for local Council
Industry: Buildings & Structures (BSTR)
Application: WPA-Wall Problem Areas (WPA)
Substrate: Other
Customer Location: Retford
Application Date: March 2024
Products: Belzona 5122 (Clear Cladding Concentrate)
Problem: An issue was identified whereby the build up and growth of mold and mildew to shaded elevations needed to be stopped or slowed down. Belzona was approached to supply a solution to alleviate the build up of mold and mildew by effectively preventing the rendered environment from absorbing moisture
Rendered property suffering a build up of mold and mildew
Preparation: Washing down the rendered walls with HP water & fungicidal wash prior to fixing any cracks or damaged rendered surfaces
The property prepared ready for the application of Belzona 5122
The property after the application of the Belzona 5122, appearing completely invisible
Application Situation
4 properties were chosen to trial the Belzona 5122 as a solution to the problematic build up of mold and mildew. It was suggested that, because of the key function of the Belzona 5122, being that it prevents water from becoming absorbed by the substrate, and also allowing the moisture from the substrate to escape, the render would become much drier and repel the propagation of mold and mildew spores.
Application Method
All target surfaces were cleaned using HP water jetting at around 1,500psi
A fungicidal wash was incorporated to help destroy the existing mold and mildew
Any defects to the render were repaired and repointed using traditional methods in line with Belzona 5122 Instructions for use
Belzona 5122 was mixed at a 9:1 ratio with clean water. 9 parts clean water to 1 part Belzona 5122
This was applied to the walls using a low pressure back-pack spray until all target surfaces were coated
Belzona Facts
There has been no sign of the return of mold or mildew and, since the trial went ahead, a further 13 properties have been listed for the same application, leading to 180 assets eventually being treated over the next 18 months